Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review
- PMID: 3076132
- DOI: 10.2165/00003495-198800365-00011
Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review
Abstract
The development of topical corticosteroids since the 1950s has opened new doors for dermatologists previously faced with treating intractable dermatoses, so that the pharmacology of topically applied corticosteroids is now reasonably well described. Manipulation of the steroid molecule has produced compounds with greater lipophilicity, fewer mineralocorticoid properties and high potency. Potency is determined through various techniques, notably the vasoconstrictor assay as well as the mitotic index suppression method and atrophogenic potential assay. The mechanism of activity of corticosteroids is thought to result, at least in part, from binding of the drug to steroid receptors, with resultant effects on the synthesis of proteins responsible for specific effects. Corticosteroids are proposed to alter the inflammatory response, and thus provide therapeutic benefits, via actions on mediator release and function, inflammatory cell function and release of lysosomal enzymes. Disadvantages of corticosteroid activity include the possibility of adrenal suppression, epidermal and dermal thinning, and local effects such as purpura, striae, and steroid-induced rosacea and perioral dermatitis. The cutaneous pharmacokinetics, particularly of absorption of topical corticosteroids, must be examined in parallel with their pharmacodynamic effects to gain a more complete understanding of activity. Many factors can affect percutaneous steroid absorption: drug lipophilicity and solubility, drug concentration, anatomical site, age of the patient, presence of skin disease and use of occlusive dressings will each influence the degree to which topically applied corticosteroids achieve their intended therapeutic results. Cutaneous metabolism is a poorly understood process at present, but one which is acknowledged to have some impact on the biotransformation of corticosteroids applied topically. Thus, although some gaps still persist in present knowledge of the pharmacology and pharmacokinetics of this important class of drugs, there can be no denying the contribution of topical corticosteroids to the therapy of dermatoses.
Similar articles
-
Current treatment guidelines for topical corticosteroids.Drugs. 1988;36 Suppl 5:9-14. doi: 10.2165/00003495-198800365-00004. Drugs. 1988. PMID: 3076133 Review.
-
Clinical potential of topical corticosteroids.Drugs. 1988;36 Suppl 5:38-42. doi: 10.2165/00003495-198800365-00008. Drugs. 1988. PMID: 3076130 Review.
-
Corticosteroids: options in the era of steroid-sparing therapy.J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S50-8. doi: 10.1016/j.jaad.2005.04.030. J Am Acad Dermatol. 2005. PMID: 15968264 Review.
-
Topical corticosteroids: clinical pharmacology and therapeutic use.Drugs. 1980 Feb;19(2):119-34. doi: 10.2165/00003495-198019020-00004. Drugs. 1980. PMID: 7363838
-
Topical corticosteroids. Which drug and when?Drugs. 1992 Jul;44(1):65-71. doi: 10.2165/00003495-199244010-00006. Drugs. 1992. PMID: 1379911 Review.
Cited by
-
Topical Steroid-Induced Perioral Dermatitis (TOP STRIPED): Case Report of a Man Who Developed Topical Steroid-Induced Rosacea-Like Dermatitis (TOP SIDE RED).Cureus. 2021 Apr 12;13(4):e14443. doi: 10.7759/cureus.14443. Cureus. 2021. PMID: 33996307 Free PMC article.
-
Understanding the correlation between structure and dynamics of clocortolone pivalate by solid state NMR measurement.RSC Adv. 2020 Jan 27;10(8):4310-4321. doi: 10.1039/c9ra09866f. eCollection 2020 Jan 24. RSC Adv. 2020. PMID: 35495240 Free PMC article.
-
Mometasone-based triple combination therapy in melasma: is it really safe?Indian J Dermatol. 2010 Oct;55(4):359-62. doi: 10.4103/0019-5154.74545. Indian J Dermatol. 2010. PMID: 21430890 Free PMC article.
-
Dermacase. Atrophic patches.Can Fam Physician. 2006 Dec;52(12):1547, 1551-2. Can Fam Physician. 2006. PMID: 17279233 Free PMC article. No abstract available.
-
Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris.Eur J Clin Pharmacol. 1990;39(4):349-51. doi: 10.1007/BF00315408. Eur J Clin Pharmacol. 1990. PMID: 2076716 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical